Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis

• Status: Completed
• Trial end date: 2004-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Procter and Gamble

Criteria

Inclusion Criteria:

• mild to moderate knee osteoarthritis confirmed by a radiographic technique.

Exclusion Criteria:

• secondary knee osteoarthritis;

• diseases other than osteoarthritis that could cause knee pain;

• any disease or intervention (surgery, intra-articular injection) that would have an impact on knee pain or mobility;

• drugs that act potentially on the bone or cartilage component of the knee joint.